The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Current Breast Cancer Reports"
DOI: 10.1007/s12609-017-0254-7
Abstract: Purpose of ReviewThis review article seeks to summarize the existent literature regarding the use of anthracyclines (specifically doxorubicin) in the treatment of early-stage breast cancers, reviewing the clinically significant side effects of said therapy, and… read more here.
Keywords: risk; breast; breast cancer; based chemotherapy ... See more keywords
Evaluation of dexrazoxane effect on preventing acute cardiac arrhythmia in patients with breast cancer treated with neoadjuvant/adjuvant anthracycline‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.14705
Abstract: Adding dexrazoxane to the treatment during neoadjuvant/adjuvant anthracycline‐based chemotherapy in patients with breast cancer prevents the development of heart failure. In this study, we investigated whether dexrazoxane has a protective effect on arrhythmia resulting from… read more here.
Keywords: patients breast; neoadjuvant adjuvant; adjuvant anthracycline; based chemotherapy ... See more keywords
Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.516
Abstract: 516Background: The MINDACT trial demonstrated that 46% of breast cancer patients (pts) at high clinical (C) but low genomic (G) risk based on MammaPrint (70-gene signature), might safely forego adjuvant CT (Cardoso NEJM 2016). A… read more here.
Keywords: anthracycline based; trial; standard anthracycline; breast cancer ... See more keywords
Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13194877
Abstract: Simple Summary High-risk soft tissue sarcomas (HR-STS) account for less than 1% of all malignancies in adults. Despite optimal local treatment, almost half of patients will die within five years of their diagnosis. Chemoresistance is… read more here.
Keywords: chemotherapy; neoadjuvant anthracycline; top2a sirt1; expression ... See more keywords